Pfizer's (PFE) RSV Vaccine Study in Adults Under 60 Meets Goal

Pfizer (PFE) announced that a phase III study evaluating its new respiratory syncytial virus (RSV) Abrysvo in adults aged 18 to 59 met its primary endpoints.Abrysvo was launched to help protect older adults as well as infants through maternal immunization in the United States as well as in the EU in 2023.The study called MONeT evaluated the immunogenicity and safety of Abrysvo versus placebo in adults aged 18 to 59 who are at an increased risk of developing severe RSV-associated lower respiratory tract dise ...